Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney Disease

Mhairi K. Sigrist,*† Maarten W. Taal,*‡ Peter Bungay,† and Christopher W. McIntyre*†

Departments of *Renal Medicine and ‡Imaging, Derby City General Hospital, Derby, and †School of Health, University of Nottingham, Nottingham, United Kingdom

Background and objectives: Vascular calcification is increasingly recognized as an important component of cardiovascular disease in chronic kidney disease. The objective of this study was to investigate prospectively the determinants, cardiovascular functional consequences, and survival associated with vascular calcification over 24 mo.

Design, setting, participants, & measurements: A total of 134 patients (60 on hemodialysis, 28 on peritoneal dialysis, and 46 with stage 4 chronic kidney disease) were studied. Vascular calcification of the superficial femoral artery was assessed using multislice spiral computed tomography; pulse wave velocity; all medications and time-averaged biochemical parameters were recorded at baseline and 12 and 24 mo.

Results: A total of 101 patients remained at 24 mo. Progressive calcification was seen in 58 of 101 patients. Most (31 of 46) patients with an initial calcification score of zero did not develop calcification. The hemodialysis group demonstrated a greater degree of progression than patients who were on peritoneal dialysis or had stage 4 chronic kidney disease. Progressive calcification was associated with age, male gender, serum alkaline phosphatase, β-blockers, and lipid-lowering agents.

Increases in vascular calcification correlated with increased arterial stiffness. Vascular calcification was present in 20 of 21 patients who died. Cox proportional hazard analysis identified change in calcification score, calcium intake from phosphate binders, and low albumin as risk factors for death.

Conclusions: Patients with stages 4 and 5 chronic kidney disease and preexisting vascular calcification exhibit significantly increased calcification over 24 mo. Rapid progression of calcification is associated with arterial stiffness and mortality.


Vascular calcification (VC) and arterial stiffness have been identified as independent predictors of all-cause and cardiovascular (CV) mortality in stage 5 chronic kidney disease (CKD) (1). More than 40% of dialysis patients will die from CV-related causes (2). The pathophysiology of vascular disease in CKD is increasingly recognized to be distinct from that related to atherosclerosis in the general population (3). Additional risk factors for vascular disease in CKD include inflammation, malnutrition, oxidative stress, and abnormal mineral metabolism (4).

The functional hemodynamic alterations that are associated with VC and the mechanisms by which arterial calcification leads to CV death are poorly understood. We and others (5–7) have found associations between VC and arterial stiffening as well as autonomic dysfunction in cross-sectional studies of patients with stages 4 to 5 CKD, but no longitudinal studies are available.

Cross-sectional studies, including our own, (8–11) have identified multiple associations with VC, including age, gender, diabetes, length of time on dialysis, markers of mineral metabolism, bone turnover, malnutrition, and inflammation, but in the absence of longitudinal data, the relevance of these factors to the progression of VC remains unclear. The small number of published studies on the progression of VC are limited by small subject numbers, qualitative assessments of calcification, and indirect associations with functional alterations of the vasculature.

The aim of this study was to evaluate prospectively the relative contributions of multiple factors that are implicated in the development and progression of VC in CKD. We aimed to compare the progression of VC in patients with stage 4 CKD with dialysis patients. Furthermore, we sought to study prospectively the association between VC and mortality. It is hoped that these data will allow identification of targets for potential modification to reduce VC and improve CV risk among patients with CKD.

Concise Methods

Patients

A total of 134 patients (60 on hemodialysis [HD], 28 on peritoneal dialysis [PD], and 46 with stage 4 CKD) were recruited from Derby City General Hospital. Patients were eligible unless they had previously undergone renal transplantation or limb amputation. Patients with...
CKD stage 4 were staged on four-variable Modification of Diet in Renal Disease (MDRD) estimated GFR (eGFR) with values between 15 and 29 ml/min per 1.73 m². The Local Regional Ethics Committee granted project approval, and written consent was obtained from participants.

**Study Design**

Multislice computed tomography (CT) and measurement of hemodynamic variables were performed at baseline and 12 and 24 mo by a single observer. Baseline data have been published previously with a full description of the method (7). Briefly, multislice CT was used to quantify calcification in a standardized section of the superficial femoral artery. Each slice was scored individually, and a calcification score (CaSc) was generated. Calcification was considered to be present when an area ≥1 mm² displayed a density >130 Hounsfield units (12). Validation studies confirmed that the scoring technique is highly reproducible. Interobserver reproducibility between the investigator and a consultant radiologist was assessed in a 1 in 20 sample. The intraclass correlation was 1 (confidence interval 1 to 1), and the coefficient of variation (CoV) was 3.9%. Repeatedly scored scans showed an intraobserver intraclass correlation of 1 (confidence interval 1 to 1) and a CoV of 2.4%. Applanation tonometry was performed at the radial artery using a SphygmoCor (AtCor Medical Pty. Ltd., West Ryde, NSW, Australia). Augmentation was assessed as a derived central pressure wave. Electrocardiogram gated pulse wave velocity (PWV) was assessed at the radial and dorsalis pedis pulses before dialysis in the HD patients. Three BP recordings were taken using an automated AND UA-767 oscillometric device (A&D Medical, San Jose, CA).

**Biochemistry**

Monthly blood samples were collected for HD patients and at regular clinic visits for PD patients and patients with stage 4 CKD. Serum phosphate (PO₄), Ca, albumin corrected calcium, albumin, intact parathyroid hormone (PTH), lipid profile, and alkaline phosphatase (ALP) were analyzed using standard autoanalyzer techniques (Roche Diagnostics [Basel, Switzerland] Modular IIP). Serum PTH was measured using the immunometric, Immulite 2000 assay (Siemens Medical, New York, NY) (normal range 7 to 53 pg/ml). A time-averaged value is given for baseline (results averaged over the 6 mo before the study) and 12- and 24-mo results (values averaged over each 12-mo period between study visits). Commercially available ELISA kits were used to assess osteoprotegerin (OPG), fetuin-A, and high-sensitivity C-reactive protein (hsCRP) from samples that were obtained at baseline and 12 mo. The OPG ELISA (Immunodiagnostic Systems, Boldon, UK) had a detection limit of 0.14 pmol/L and a CoV of 10 to 4%. The fetuin-A ELISA (Biovendor, Modrice Czech Republic) had a detection limit of 0.35 ng/ml, and the hsCRP (DRG Instruments, Marburg/Iahn, Germany) detection limit was 0.1 mg/L and CoV was 7 to 2%.

**Statistical Analyses**

Results are reported as means ± SD for normally distributed data and median (inter quartile range [IQR]) otherwise. Comparisons of paired data were performed using paired sample t test for parametric data and Wilcoxon matched paired test for nonparametric data. Comparisons of more than two sets of data were performed using one-way ANOVA (with Bonferroni post hoc analysis for multiple comparisons) or Kruskal-Wallis tests depending on distribution. χ² tests were used to compare categorical data. Correlation coefficients were generated using R Spearman (r) tests for nonparametric data (i.e., bimodal distribution of CaSc). Mann-Whitney U tests were used to compare skewed variables between two groups.

Multiple attempts were made to normalize the distribution of CaSc; however, the bimodal distribution of CaSc, the high number of zero scores, and tails at both extremes prevented successful transformation of the data for linear regression analysis. Instead, ordinal regression analysis, with CaSc divided into quartiles, was chosen as the most meaningful method of analysis. The following baseline independent categorical variables were entered into regression analysis as determinants of CaSc: Modality group (HD, PD, or stage 4 CKD); ethnicity; gender; diabetes (yes/no); previous CV morbidity (yes/no); history of parathyroidectomy (yes/no); and the use of phosphate binders, 1α-calcidol, corticosteroids, lipid-lowering agents, diuretics, angiotensin-converting enzyme inhibitors, Ca channel antagonists, warfarin, erythropoetin, or β blockers. The following baseline independent continuous variables were entered into regression analysis as determinants of CaSc: Age, weight, body mass index (BMI), smoking history (pack-years), alcohol intake, eGFR, elemental Ca intake from phosphate binders, time-averaged PO₄, time-averaged albumin corrected calcium, time-averaged albumin, time-averaged PTH, time-averaged ALP, time-averaged lipids, baseline OPG, baseline hsCRP, and baseline fetuin-A. Cox proportional hazard analysis was performed using time to death as the dependent variable and all of the previously mentioned variables as well as change in CaSc (ΔCaSc; divided by 10 for increased units). A Kaplan-Meier plot was used to compare the survival of patients with and without VC. Statistics were generated using SPSS 12.0.1 (SPSS, Chicago, IL).

**Results**

**Study Population**

Baseline characteristics of study patients are shown in Table 1. Only CaSc and eGFR as well as use of phosphate binders, angiotensin-converting enzyme inhibitors, and β blockers were significantly different between the groups at baseline. At 24 mo, 101 of 134 patients remained to be studied, including four patients who had received a transplant (12 patients were lost to follow-up, and 21 died). Twenty-five of 46 patients with stage 4 CKD initiated dialysis during the study period (11 PD and 14 HD). Table 2 shows time-averaged biochemical variables at 12 and 24 mo. The population had good biochemical control, particularly serum PO₄ and Ca.

VC

During 24 mo, overall CaSc increased from a median of 12 (IQR 0 to 334) at baseline to 53 (IQR 0 to 480; P < 0.0001). CaSc increased in 58 of 101 patients (P < 0.0001). Figure 1 shows the increase in CaSc by modality group (categorized according to modality at 24 mo) at 12 and 24 mo. The HD group demonstrated a greater degree of progression than the PD or stage 4 CKD group at both 12 (P = 0.002) and 24 mo (P = 0.01). The rate of progression of CaSc was constant during the 24 mo of follow-up (median progression was 65 CaSc units per year between baseline and 12 mo in comparison with 54 CaSc units per year between 12 and 24 mo).

Thirty-one patients with a CaSc of zero at baseline remained free of calcification throughout the study (eight with stage 4 CKD, 11 on PD, and 11 on HD). During the first 12-mo period, calcification was initiated in eight (17%) of 46 patients (median CaSc 4) followed by another six (15%) of 38 patients during the second 12-mo period (median CaSc 4). Regression of CaSc was observed in five patients at 12 mo (median decrease 28 ± 20%) and eight patients at 24 mo (median decrease 52 ± 40%). No
and the use of lipid-lowering agents and of VC was associated with gender, age, time-averaged ALP, binders, the use of sevelamer, or any other prescribed medication (0.64; Table 4).

- Age and inversely with albumin and the use of lipid-lowering therapy.
- CaSc baseline to 24 mo correlated with baseline CaSc and (P = 0.001).
- Calcium channel blockers (n [%])
- Use of ACE inhibitors (n [%])
- Use of β blockers (n [%])

Determinants of VC

Table 2 shows results of biochemical measurements that were performed on the study patients. Progressive calcification (ΔCaSc baseline to 24 mo) correlated with baseline CaSc and age and inversely with albumin and the use of lipid-lowering agents (Table 3). No associations were found between ΔCaSc and time-averaged Ca, PO4, PTH, hsCRP, Ca from phosphate binders, the use of sevelamer, or any other prescribed medications. Ordinal regression analysis showed that the progression of VC was associated with gender, age, time-averaged ALP, and the use of lipid-lowering agents and β blockers (model \( r^2 = 0.64 \); Table 4).

Analysis of the modality groups separately showed similar overall associations with VC, with a few exceptions. It is interesting that in patients with stage 4 CKD, the reduction in eGFR correlated with ΔCaSc (\( r = -0.478, P < 0.05 \)). When patients who were free of VC were compared with those with VC, patients who were free of calcification had significantly lower weight (69 ± 12 versus 79 ± 12 kg; \( P = 0.001 \)), lower BMI (26 ± 4 versus 27 ± 4 kg/m²; \( P = 0.04 \)), and higher HDL cholesterol (1.5 ± 0.4 versus 1.3 ± 0.4; \( P = 0.014 \)). In contrast to previous reports, we found no association between VC and fetuin-A in the whole population or within modality groups. Low fetuin-A levels were observed in all three groups (0.22 ± 0.1, 0.24 ± 0.2, and 0.25 ± 0.1 g/L for PD, HD, and stage 4 CKD, respectively; normal range 0.4 to 1 g/L) (13). In addition, we observed no association between fetuin-A and hsCRP (Figure 2).

CV Consequences of VC

Hemodynamic variables that were measured at baseline and 12 and 24 mo are shown in Table 2, with significant changes highlighted. ΔCaSc correlated with pulse pressure (r = 0.216,
Table 2. Biochemical and hemodynamic variables in all patients at baseline and 12 and 24 mo

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline (n = 134)</th>
<th>12 Mo (n = 117)</th>
<th>24 Mo (n = 101)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.6 ± 1.0</td>
<td>4.2 ± 0.9&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.0 ± 1.0&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.30 ± 0.30</td>
<td>1.32 ± 0.30</td>
<td>1.37 ± 0.40&lt;sup&gt;c,d&lt;/sup&gt;</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.29 ± 0.90</td>
<td>1.84 ± 0.70&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.78 ± 0.80&lt;sup&gt;c,d&lt;/sup&gt;</td>
</tr>
<tr>
<td>PO₄ (mmol/L)</td>
<td>1.59 ± 0.36</td>
<td>1.62 ± 0.35</td>
<td>1.55 ± 0.30&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>CCa (mmol/L)</td>
<td>2.45 ± 0.13</td>
<td>2.45 ± 0.14</td>
<td>2.45 ± 0.12</td>
</tr>
<tr>
<td>Ca × PO₄ (mmol²/L²)</td>
<td>3.90 ± 0.90</td>
<td>3.98 ± 0.88</td>
<td>3.78 ± 0.84</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>257 ± 233</td>
<td>379 ± 367&lt;sup&gt;b&lt;/sup&gt;</td>
<td>404 ± 383&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALP (IU/L)</td>
<td>102 ± 55</td>
<td>123 ± 93&lt;sup&gt;b&lt;/sup&gt;</td>
<td>128 ± 75&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>32 ± 5</td>
<td>33 ± 4</td>
<td>34 ± 4&lt;sup&gt;c,d&lt;/sup&gt;</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>9.6 ± 18</td>
<td>10.9 ± 21</td>
<td>–</td>
</tr>
<tr>
<td>Osteoprotegerin (pmol/L)</td>
<td>27 ± 9</td>
<td>30 ± 11&lt;sup&gt;b&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Fetuin-A (ng/ml)</td>
<td>0.24 ± 0.14</td>
<td>0.27 ± 0.09&lt;sup&gt;b&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>149 ± 28</td>
<td>144 ± 24&lt;sup&gt;b&lt;/sup&gt;</td>
<td>138 ± 23&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>80 ± 15</td>
<td>77 ± 12&lt;sup&gt;b&lt;/sup&gt;</td>
<td>76 ± 13&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pulse pressure (mmHg)</td>
<td>68 ± 23</td>
<td>67 ± 23</td>
<td>62 ± 20&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>70 ± 13</td>
<td>72 ± 16</td>
<td>74 ± 16&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Augmentation (mmHg)</td>
<td>15 ± 10</td>
<td>16 ± 14</td>
<td>14 ± 11</td>
</tr>
<tr>
<td>Augmentation index (p1/p2)</td>
<td>139 ± 22</td>
<td>137 ± 34</td>
<td>116 ± 48&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>PWV (m/s)</td>
<td>10.3 ± 3.4</td>
<td>11.2 ± 4.7</td>
<td>9.7 ± 3.5&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Biochemical results are time averaged. Data are means ± SD. ALP, alkaline phosphatase; CCa, albumin corrected calcium; hsCRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone.

<sup>b</sup>Significant differences between baseline and 12 mo (P < 0.05).

<sup>c</sup>Significant differences between baseline and 24 mo (P < 0.05).

<sup>d</sup>Significant differences between 12 and 24 mo (P < 0.05).

Figure 1. Change in calcification score over 24 mo. Calcification scores (CaSc) are shown for the groups (patients with stage 4 chronic kidney disease [CKD; n = 16], peritoneal dialysis [PD; n = 26] patients, and hemodialysis [HD; n = 55] patients) at 12 and 24 mo. CaSc significantly increased from baseline at both 12 (stage 4 CKD P = 0.005, PD P < 0.001, and HD P < 0.001) and 24 mo (stage 4 CKD P = 0.001, PD P < 0.001, and HD P < 0.001). The HD group demonstrated a significantly higher increase in CaSc than the PD or stage CKD 4 group at both 12 (P = 0.002) and 24 mo (P = 0.01).

P < 0.05) and PWV (r = 0.329, P < 0.05) and inversely with diastolic BP (r = −0.294, P < 0.05) at 24 mo. It is interesting that ΔCaSc correlated significantly with increased arterial stiffening (ΔPWV) at both 12 (r = 0.52, P < 0.001) and 24 mo (r = 0.33, P = 0.003; Figure 3).

Mortality

Of the original 134 patients, 21 died. Twenty of 21 patients who died had VC. The single mortality without VC was due to metastatic uroepithelial malignancy (Figure 4). Forty percent of patients died of CV-related causes. Mortality in the modality groups was 52% in HD, 33% in PD, and 14% stage 4 CKD. Cox proportional hazard analysis identified three factors that were associated with reduced survival: ΔCaSc, calcium intake from phosphate binders, and low albumin at baseline (Table 5).

Discussion

We found that patients with stages 4 and 5 CKD and preexisting VC exhibit progression of calcification at a continuous rate over 24 mo. These data show that progressive calcification of
the superficial femoral artery is associated with an incremental increase in arterial stiffness. In addition, the progression of VC, the use of calcium-containing phosphate binders, and reduced albumin were independent factors associated with death.

Rapid progression of VC was seen in 57% of patients. Other studies have found comparable rates of progression in PD and HD (8,14). This rate of progression has not previously been appreciated in patients with stage 4 CKD. Conversely, 4 to 8% of patients demonstrated regression. This shows that VC is a dynamic process, and its progression could be modified if appropriate strategies for therapeutic intervention were identified. Thirty percent of patients across all modalities remained free of VC after 24 mo. This finding is consistent with previous observational studies of VC (15). These patients are not, however, exempt from developing calcification. Thirty percent of patients across all modalities remained free of VC after 24 mo. This finding is consistent with previous observational studies of VC (15). These patients are not, however, exempt from developing calcification. Seven percent of patients who are free of calcification could provide answers to the protective mechanisms involved.

The arterial calcification score generated by CT scanning is a composite of both medial and intimal calcification or calcified athero- and arteriosclerosis. These coexisting abnormalities have different pathologies. This is reflected in the multifactorial determinants of the progression of VC found in this and other studies. Consistent with other studies (8,10), we found that age and male gender were important determinants of VC. These patients are also the most likely to have intimal arterial disease (1). Other atherosclerotic risk factors were associated with VC in this study. The negative association seen in this study between the use of lipid-lowering agents and VC could reflect

Table 4. Determinants of VC progression during 24 moa

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>1.11 (1.05 to 1.16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male gender</td>
<td>8.82 (1.82 to 42.65)</td>
<td>0.007</td>
</tr>
<tr>
<td>ALP (IU/L)</td>
<td>1.02 (1.00 to 1.03)</td>
<td>0.01</td>
</tr>
<tr>
<td>Lipid-lowering agents (yes)</td>
<td>0.27 (0.08 to 0.86)</td>
<td>0.03</td>
</tr>
<tr>
<td>β blockers (yes)</td>
<td>0.27 (0.08 to 0.95)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

aOrdinal regression analysis was used with Δ CaSc as the dependent variable (model $R^2 = 0.64$). CI, confidence interval; OR, odds ratio.

Figure 2. Scatter plot of the association between tertiles of fetuin-A and high-sensitivity C-reactive protein (hsCRP) in all study patients at baseline ($P = 0.42$).

Figure 3. (A) Scatter plot of change in CaSc ($\Delta$CaSc) plotted against change in pulse wave velocity ($\Delta$PWV [m/s]) at 12 mo ($r = 0.52, P < 0.001$). (B) Scatter plot of $\Delta$CaSc plotted against $\Delta$PWV (m/s) at 24 mo ($r = 0.33, P = 0.003$).

Figure 4. Kaplan-Meier plot of survival in patients with and without calcification of the superficial femoral artery at baseline.
lower atherosclerotic burden as a result of a reduction in cholesterol. In addition, low serum albumin was associated with progressive VC, in keeping with previous studies of VC (11,16). Albumin, an abundant plasma protein, has been identified as a mediator of vascular damage in dialysis patients independent of calcification (17). Low serum albumin is directly predictive of CV death in dialysis patients (18). Hypoalbuminemia may reflect inflammation and/or malnutrition, both associated with atherosclerosis in CKD (19,20). Low albumin levels seen here could be due to either, because the hsCRP levels were moderately raised. We found no association between hsCRP and VC; however, the importance of inflammation cannot be discounted, because no other circulating markers of inflammation were measured. Fetuin-A, a negative acute-phase reactant in nonuremic individuals, has been identified as an inhibitor of calcification in murine models. Again, we found no relationship between fetuin-A and hsCRP, questioning whether it is truly a marker of inflammation in our population. In addition, all patients had low serum fetuin-A levels (13). We found no association between VC and circulating fetuin-A. Hermans et al. (21) investigated the potential relationship between fetuin-A and PWV and published similar negative findings.

In the general elderly population, progressive VC is solely associated with age and atherosclerotic risk factors (22). Calcification of the media seen predominantly in patients with CKD is associated with additional factors, which may be unique to CKD. In other studies (15), elevated serum calcium and phosphate are commonly (but not consistently) associated with VC. Our population was characterized by excellent mineral control, which may explain why there was no association seen in this study. Braun et al. (23) showed that patients with the worst phosphate control had the most rapid progression of VC. The use of sevelamer, in comparison with calcium-based phosphate binders, is the only intervention that has been shown to attenuate the progression of VC; however, this could be related to the lipid-lowering properties of sevelamer (24). In this study, there was no association between progressive VC and the type or dosage of phosphate binder. It is important to note that calcification still advances in patients with well-controlled mineral levels and no calcium from phosphate binders (25). ALP was associated with the progression of VC. Circulating ALP in this setting could be directly involved in the calcification process or a marker of bone activity, although we found no association between PTH and VC. There is evidence that ALP has localized effects on the vessel, particularly in patients with diabetes, although this requires further elucidation (26). The use of β blockers was also associated with the progression of VC. β Blockers inhibit the β adrenoreceptors in the heart and peripheral vasculature and may promote VC through modulating sympathetic activity and trophic effects on peripheral vasculature. VC in HD patients is associated with reduced baroreflex sensitivity (6). In addition, β blockers can directly modulate skeletal function in murine models (27).

It is interesting that preexisting VC was a strong determinant of progression. Block et al. (15) also found this in 109 incident HD patients. In addition, HD seems to exacerbate calcification more than PD. PD patients had a similar rate of progression to patients who had not yet started on dialysis. The reasons for this are unclear, although the PD population had a higher residual kidney function and, less VC at baseline and used more Ca-containing phosphate binders. The ordinal regression analysis accounts for 64% of the variability, which suggests that additional factors are involved. Taken together, our data suggest that there is a complex interaction between atherogenic and CKD-specific risk factors along with additional unspecified risk factors, which drive the progression of VC in patients with CKD.

Progressive calcification in this cohort is associated with an increase in arterial stiffness, high pulse pressure, and low diastolic BP. Cross-sectional studies (28) have shown that VC is associated with arterial stiffening. Blacher et al. (5,28) found that VC correlated with increased PWV, increased pulse pressure, and decreased diastolic BP. We have shown for the first time that these variables change in parallel over time. Incremental increases in PWV and pulse pressure have been observed in patients with increasing stages of CKD (29). Chronic hypertension rather than VC was previously used to explain this observation; however, Briet et al. (30) demonstrated altered vascular structure and arterial stiffening in patients with stages 3 and 4 CKD compared with a hypertensive population with normal renal function. It is clear, though, that PWV is not continuously on an increasing trajectory. PWV is affected by multiple factors, and the decreased PWV that is seen in some patients could reflect improved fluid management, improved BP control, or a change in vasoactive medication. This study demonstrates that VC is a highly active process that is directly related to vascular function, rather than an inert component of atherosclerosis or arteriosclerosis.

We observed that progressive calcification during 12 mo is independently predictive of death in patients with stages 4 and 5 CKD. This was despite the inclusion of more conventional mortality risk factors (e.g., age, CV comorbidities) into the model. The association between VC at a single time point and mortality was observed previously in homogeneous HD groups (1,31). The mechanisms whereby VC contributes to CV death are not fully understood, but we propose that the arterial stiffness that is associated with VC leads to increased left ventricular afterload and decreased diastolic coronary perfusion. The amount of Ca delivered from calcium-based phosphate binders was also an independent predictor of death. Block et al. (31) recently demonstrated that death was three times more
likely in patients who used calcium-containing phosphate binders, rather than sevelamer, in a population of incident HD patients. The third determinant of reduced survival was a low serum albumin, which probably reflects malnutrition and has been associated with death in other studies conducted in patients with CKD (18).

Limitations to this study include the relatively small patient numbers in the three groups; this potentially limited the relevance of intergroup statistical analysis with particular reference to the drivers of VC. The observed associations between β blockers and lipid-lowering agents should be interpreted with caution, because these agents were not prescribed as part of a randomized study. In addition, a randomized, controlled trial would be necessary to confirm the observational findings from this study.

Conclusions

These data demonstrate rapidly progressive VC in comparable populations of HD and PD patients and patients with stage 4 CKD. Several potentially modifiable determinants of VC progression have been identified. Given its associations with CV mortality, preventing the progression of VC should become a clinical target in the treatment of patients with CKD. In view of our observations, in patients with stage 4 CKD, early intervention and aggressive management of the progression of VC needs to begin before the initiation of renal replacement therapy.

Acknowledgments

M.K.S. is funded to conduct this research through a 2-yr fellowship from Kidney Research UK/British Renal Society. Additional funding for this study was awarded through a Derby Hospitals NHS Foundation Trust research grant.

We acknowledge sister Carol Rhodes and staff on the renal unit in Derby for accommodating and supporting this project. In addition, we acknowledge Apostolos Fakis for expert statistical advice.

Disclosures

None.

References

18. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and


